Cemiplimab prolongs survival in recurrent cervical cancer
New research shows kids can help families cut salt consumption
11 February 2022Prior SARS-CoV-2 infection less protective against Omicron variant
11 February 2022Cemiplimab prolongs survival in recurrent cervical cancer
(HealthDay)—For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab than with single-agent chemotherapy, according to a study published in the Feb. 10 issue of the New England Journal of Medicine.
